A detailed history of Jane Street Group, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 66,718 shares of RNA stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,718
Previous 162,039 58.83%
Holding current value
$2.33 Million
Previous $6.62 Million 53.71%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$37.21 - $48.14 $3.55 Million - $4.59 Million
-95,321 Reduced 58.83%
66,718 $3.06 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $1.14 Million - $2.05 Million
50,125 Added 44.79%
162,039 $6.62 Million
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $381,596 - $1.06 Million
41,659 Added 59.3%
111,914 $2.86 Million
Q4 2023

Feb 14, 2024

SELL
$4.87 - $9.37 $488,933 - $940,719
-100,397 Reduced 58.83%
70,255 $635,000
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $52,869 - $95,249
8,392 Added 5.17%
170,652 $1.09 Million
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $1.01 Million - $1.64 Million
94,773 Added 140.43%
162,260 $1.8 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $773,593 - $1.29 Million
50,397 Added 294.89%
67,487 $1.04 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $171,925 - $387,259
17,090 New
17,090 $379,000
Q2 2022

Aug 16, 2022

BUY
$11.18 - $20.5 $512,278 - $939,330
45,821 New
45,821 $666,000
Q4 2021

Feb 15, 2022

SELL
$20.4 - $28.66 $226,133 - $317,696
-11,085 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$18.16 - $25.21 $201,303 - $279,452
11,085 New
11,085 $273,000
Q3 2020

Nov 17, 2020

SELL
$23.35 - $35.94 $331,149 - $509,701
-14,182 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$26.62 - $31.5 $377,524 - $446,733
14,182 New
14,182 $401,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.82B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.